Coagulation problems in dialysis patients

Complications of Dialysis

Volumn , Issue , 2000, Pages 327-341

  Boccardo, Paola ^a   Remuzzi, Giuseppe ^b  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b OSPEDALI RIUNITI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 12244271663     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (151)

1. Riesman D. Hemorrhages in the course of Bright’ disease with special reference to the occurrence of a hemorrhagic diathesis of nephritic origin. Am J Med Sci 1907; 134: 709.
2. Gross R, Nieth H, Mammen E. Blutungsbereitschaft und Gerrinungstörungen bei Uramie. Klin Woschr 1958; 36: 107.
3. Larsson SO. On coagulation and fibrinolysis in renal failure. Scand J Haematol 1971; 15: 1.
4. Rabiner SF. Bleeding in uremia. Med Clin North Am 1972; 56: 221.
5. Watson AJ, Gimenez LF. The bleeding diathesis of uremia. Semin Dial 1991; 4: 86-93.
6. Steiner RW, Coggins C, Carvalho ACA. Bleeding time in uremia: a useful test to assess clinical bleeding. Am J Hematol 1979; 7: 107-117.
7. Lind SC. Prolonged bleeding time. Am J Med 1984; 77: 305-312.
8. Kumar R, Ansell JE, Conaso RT, Duykin D. Clinical trial of a new bleeding time device. Am J Clin Pathol 1978; 70: 642-645.
9. Burns ER, Lawrence C. Bleeding time: a guide to its diagnostic and clinical utility. Arch Pathol Lab Med 1989; 113: 1219-1224.
10. Liu YK, Goldstein DM, Arora K, Woo D, Ferris FZ, Marcum SG, Garrison RN, Amin M. Thigh bleeding time as a valid indicator of hemostatic competency during surgical treatment of patients with advanced renal disease. Surg Gynecol Obstet 1991; 172: 269-274.
11. Lindsay RM, Moorthy AV, Koens F, Linton AL. Platelet function in dialyzed and non-dialyzed patients with chronic renal failure. Clin Nephrol 1975; 4: 52-57.
12. Eknoyan G, Wacksman SJ, Glueck HI, Will JJ. Platelet function in renal failure. N Engl J Med 1969; 280: 677-681.
13. Gafter U, Bessler H, Malachi T, Zevin D, Djaldetti M, Levi J. Platelet count and thrombopoietic activity in patients with chronic renal failure. Nephron 1987; 45: 207-210.
14. Lindsay RM, Prentice CR, Davidson JF, Burton JA, McNicol GP. Hemostatic changes during dialysis associated with thrombus formation on dialysis membranes. Br Med J 1972; 4: 454.
15. Di Minno G, Martinez J, McKean M, De La Rosa J, Burke JF, Murphy S. Platelet dysfunction in uremia. Multifaceted defect partially corrected by dialysis.Am J Med 1985; 79: 552-559.
16. Eknoyan G, Brown CH. Biochemical abnormalities of platelets in renal failure. Evidence for decreased platelet serotonin, adenosine diphosphate and Mg-dependent adenosine triphosphatase. Am J Nephrol 1981; 1: 17-23.
17. Vlachoyannis J, Schoeppe W. Adenylate cyclase activity and cAMP content of human platelets in uremia. Eur J Clin Invest 1982; 12: 379-381.
18. 2+ in platelets from patients with uremia. Blood 1989; 73: 172-176.
19. Remuzzi G, Benigni A, Dodesini P, Schieppati A, Livio M, Poletti G, Mecca G, de Gaetano G. Parathyroid hormone inhibits human platelet function. Lancet 1981; 2: 1321-1323.
20. Benigni A, Livio M, Dodesini P, Schieppati A, Panigada M, Mecca G, de Gaetano G, Remuzzi G. Inhibition of human platelet aggregation by parathyroid hormone: Is cyclic AMP implicated? Am J Nephrol 1985; 5: 243-247.
21. Viganò G, Gotti E, Comberti E, Giangrande A, Trevisan R, Remuzzi G. Hyperparathyroidism does not influence the abnormal primary haemostasis in patients with chronic renal failure. Nephrol Dial Transplant 1989; 4: 971-974.
22. Rabiner SF. Uraemic bleeding. In: Spaet TH, ed. Progress in Hemostasis and Thrombosis. New York: Grune & Stratton, 1972: 233-250.
23. Remuzzi G, Benigni A, Dodesini P, Schiepapti A, Gotti E, Livio M, Mecca G, Dondi MB, de Gaetano G. Platelet function in patients on maintenance hemodialysis: depressed or enhanced? Clin Nephrol 1982; 17: 60-63.
24. Zicker MB. Biological aspects of heparin action. Heparin and platelet function. Fed Proc 1977; 36: 47-49.
25. Di Minno G, Martinez J, McKean ML, De La Rosa J, Burke JF, Murphy S. Platelet dysfunction in uremia. Multifaceted defect partially corrected by dialysis.Am J Med 1985; 79: 552-559.
26. Evans EP, Branch RA, Bloom AL. A clinical and experimental study of platelet function in chronic renal failure. J Clin Pathol 1987; 25: 745-753.
27. Smith MC, Dunn MJ. Impaired platelet thromboxane production in renal failure. Nephron 1981; 29: 133-137.
28. Remuzzi G, Benigni A, Dodesini P, Schieppati A, Livio M, de Gaetano G, Day JS, Smith WL, Pinca E, Patrignani P, Patrono C. Reduced platelet thromboxane formation in uremia. Evidence for a functional cyclooxygenase defect. J Clin Invest 1983; 71: 762-768.
29. Macconi D, Viganò G, Bisogno G, Galbusera M, Orisio S, Remuzzi G, Livio M. Defective platelet aggregation in response to platelet-activating factor in uremia associated with low platelet thromboxane A2 generation. Am J Kidney Dis 1992; 19(4): 318-325.
30. Livio E, Benigni A, Remuzzi G. Coagulation abnormalities in uremia. Semin Nephrol 1985; 5(2): 82-90.
31. Remuzzi G, Perico N, Zoja C, Corna D, Macconi D, Viganò G. Role of endothelium-derived nitric oxide in the bleeding tendency of uremia. J Clin Invest 1990; 86: 1768-1771.
32. Ignarro LJ. Endothelium-derived nitric oxide: actions and properties. Fed Am Soc Exp Biol J 1988; 3: 31-36.
33. Radomski MW, Palmer RMJ, Moncada S. The role of nitric oxide and cGMP in platelet adhesion to vascular endothelium. Biochem Biophys Res Comm 1987; 148: 1482-1489.
34. Noris M, Benigni A, Boccardo P, Aiello S, Gaspari F, Todeschini M, Figliuzzi M, Remuzzi G. Enhanced nitric oxide synthesis in uremia: implications for platelet dysfunction and dialysis hypotension. Kidney Int 1993; 44: 445-450.
35. Schmitt GW, Moake JL, Rudy CK, Vicks SL, Hamburger RJ. Alterations in hemostatic parameters during hemodialysis with dialyzers of different membrane composition and flow design. Am J Med 1983; 83: 411-418.
36. Benigni A, Boccardo P, Galbusera M, Monteagudo J, De Marco L, Remuzzi G, Ruggeri ZM. Reversible activation defect of the platelet glycoprotein IIb-IIIa complex in patients with uremia. Am J Kidney Dis 1993; 22: 668-676.
37. Rabiner SF, Molinas F. The role of phenol and phenolic acid on the thrombocytopathy and defective platelet aggregation of patients with renal failure. Am J Med 1970; 49: 346-351.
38. Horowitz HI, Stein IM, Cohen BD, White JG. Further studies on the platelet inhibiting effect of guanidinosuccinic acid and its role in uremic bleeding. Am J Med 1970; 49: 336-340.
39. Remuzzi G, Livio M, Marchiaro G, Mecca G, de Gaetano G. Bleeding in renal failure: altered platelet function in chronic uraemia only partially corrected by haemodialysis. Nephron 1978; 22: 347-353.
40. Rabiner SF. Bleeding in uremia. Med Clin North Am 1972; 56: 221-223.
41. Eknoyan G, Wacksman SJ, Glueck HI, Will JJ. Platelet function in renal failure. N Engl J Med 1969; 280: 677-681.
42. Castillo R, Lozano T, Escolar G, Revert L, Lopez J, Ordinas A. Defective platelet adhesion on vessel subendothelium in uremic patients. Blood 1986; 65: 337-342.
43. Escolar G, Cases A, Bastida E, Garrido M, Lopez J, Revert L, Castillo R, Ordinas A. Uremic platelets have a functional defect affecting the interaction of von Willebrand factor with glycoprotein IIb-IIa. Blood 1990; 76: 1336-1340.
44. Remuzzi G, Cavenaghi AE, Mecca G, Donati MB and De Gaetano G. Prostacyclin-like activity and bleeding in renal failure. Lancet 1977; 2: 1195-1197.
45. Remuzzi G, Marchesi D, Livio M, Schieppati A, Mecca G, Donati MB, de Gaetano G. Prostaglandins, plasma factors and haemostasis in uraemia. In: Remuzzi G, Mecca G, De Gaetano G, eds. Hemostasis, Prostaglandins and Renal Disease. New York: Raven Press, 1980: 273-281.
46. Leithner CH, Winter M, Sibauer K, Wagner O, Pinggera W, Sinzinger H. Enhanced prostacyclin availability of blood vessels in uraemic humans and rats. In: Robinson RHB, Hawkins JB, eds. Dyalysis Transplantation Nephrology. Proceeding of the 15th Congress of European Dialysis and Transplant Association. Tunbridge Wells: Pitman Medical, 1978: 418-422.
47. Zoja C, Viganò G, Bergamelli A, Benigni A, De Gaetano G, Remuzzi G. Prolonged bleeding time and increased vascular prostacyclin in rats with chronic renal failure: effects of conjugated estrogens. J Lab Clin Med 1988; 112: 380-386.
48. Defreyn G, Vergara Dauden M, Machin SJ, Vermylen J. A plasma factor in uraemia which stimulates prostacyclin release from cultured endothelial cells. Thromb Res 1980; 19: 695-699.
49. Saglikes Y, Massry SG, Iseki K, Nadles JL, Campese VM. Effect of PTH on blood pressure and response to vasoconstrictor agonists. Am J Physiol 1985; 248: F674-F681.
50. Gordge MP, Neild GH. Platelet function in uraemia. Platelets 1991; 2: 115-123.
51. Kazatchkine N, Sulta V, Caen JP, Bartiery J. Bleeding in uremia: a possible cause. Br Med J 1976; 2: 612-615.
52. Hermann RP, Marshall LR, Hurst PE. Bleeding in renal failure: a possible cause. Br Med J 1977; 1: 1601-1602.
53. Remuzzi G, Livio M, Roncaglioni MC, Mecca G, Donati MB and De Gaetano G. Bleeding in renal failure: Is von Willebrand factor implicated? Br Med J 1977; 2: 359-361.
54. Warrell RP Jr, Hultin MB, Coller BS. Increased factor VIII/von Willebrand factor antigen and von Willebrand factor activity in renal failure. Am J Med 1979; 66: 226-228.
55. Janson PA, Jubelirer SJ, Weinstein MJ, Deykin D. Treatment of bleeding tendency in uremia with cryoprecipitate. N Engl J Med 1980; 303: 1319-1322.
56. Mannucci PM, Remuzzi G, Pusinieri F, Lombardi R, Valsecchi C, Mecca G, Zimmerman TS. Deamino-8-D-arginine vasopressin shortens the bleeding time in uremia. N Engl J Med 1983; 308: 8-12.
57. Turnitto WT, Weiss HT. Red blood cells: their dual role in thrombus formation. Science 1980; 207: 541-543.
58. Sakariassen KS, Bollhuid PA, Sixma JJ. Platelet adherence to sub-endothelium of human arteries in pulsatile and steady flow. Thromb Res 1980; 19: 547-559.
59. Gaarder A, Jonsen J, Lland S, Hellem A, Owren PS. Adenosine diphosphate in red cells as a factor in the adhesiveness of human blood platelets. Nature 1961; 192: 531-532.
60. 2) by human erythrocytes. Br J Haematol 1983; 54: 43-52.
61. Livio M, Gotti E, Marchesi D, Mecca G, Remuzzi G, De Gaetano G. Uraemic bleeding: role of anemia and beneficial effect of red cell transfusions. Lancet 1982; 2: 1013-1015.
62. Fernandez F, Goudable C, Sie P, Ton-That H, Durand D, Suc JM, Boneu B. Low hematocrit and prolonged bleeding time in uraemic patients: effect of red cell transfusions. Br J Haematol 1985; 59: 139-148.
63. Aznar-Salatti J, Hernandez R, Anton P, Cases A, Escolar G, Ordinas A. Serum obtained from uraemic patients modifies the reactivity towards platelets of extracellular matrices produced by endothelial cells (abstr). VIth International Symposium on the Biology of Vascular Cells 1990; 1: 57.
64. Gordge MP, Leaker BR, Patel A, Oviasu E, Cameron JS, Neild GH. Recombinant human erythropoietin corrects uraemic bleeding without causing intravascular haemostatic activation. Thromb Res 1990; 57: 171-182.
65. Moia M, Mannucci PM, Vizzotto L, Casati S, Cattaneo M, Ponticelli C. Improvement in the haemostatic defect of uraemia after treatment with recombinant human erythropoietin. Lancet 1987; 2: 1227-1229.
66. Viganò G, Benigni A, Mendogni D, Mingardi G, Mecca G, Remuzzi G. Recombinant human erythropoietin to correct uremic bleeding. Am J Kidney Dis 1991; 1: 44-49.
67. Eiser AR. Gastrointestinal bleeding in maintenance dialysis patients. Semin Dial 1988; 1: 198-202.
68. Dinoso VP Jr, Murthy SN, Saris AL, Clearfield HR, Lyons P, Nickey WA, Simonian S. Gastric and pancreatic function in patients with end-stage renal disease. J Clin Gastroenterol 1982; 4: 321-324.
69. Kleinknecht D, Jungers P, Chanard J, Barbanel C, Ganeval D. Uremic and non-uremic complications in acute renal failure. Evaluation of early and frequent dialysis on prognosis. Kidney Int 1972; 1: 190-196.
70. Shepherd AM, Stewart WK, Wormsley KG. Peptic ulceration in chronic renal failure. Lancet 1973; 1: 1357-1359.
71. Margolis DM, Saylor JL, Geisse G, De Schryver-Kecskemeti K, Harter HR, Zuckerman GR. Upper gastrointestinal disease in chronic renal failure: a prospective evaluation. Arch Int Med 1978; 138: 1214-1217.
72. Dave PB, Romeu J, Antonelli A, Eiser AR. Gastrointestinal telangiectasias: a source of bleeding in patients receiving hemodialysis. Arch Int Med 1984; 144: 17810-1783.
73. Boley SJ, Sammartano R, Adams A. On the nature and aetiology of vascular ecstasias of the colon. Degenerative lesions of aging. Gastroenterology 1977; 72: 652-660.
74. Zuckerman GR, Cornette GL, Clouse RE, Harter HR. Upper gastrointestinal bleeding in patients with chronic renal failure. Ann Int Med 1978; 138: 1214-1217.
75. Cunningham JT. Gastric telangiectasis in chronic hemodialysis patients: a report of six cases. Gastroenterology 1981; 81: 1131-1133.
76. Dorothy CC. Gastrointestinal bleeding in dialysis patients. Nephron 1993; 63: 132-139.
77. Kumar S, Lesch M. Pericarditis in renal disease. Prog Cardiovasc Dis 1980; 22: 357-369.
78. Rutsky EA, Rostand SG. Treatment of uraemic pericarditis and pericardial effusion. Am J Kidney Dis 1987; 10: 2-8.
79. Comty CM, Shapiro FL. Cardiac complications of regular dialysis therapy. In: Maher J, ed. Replacement of Renal Function by Dialysis. Dordrecht: Kluwer Academic Publishers, 1983: 33-70.
80. Drueke T, Le Pailleur C, Zingraff J, Jungers P. Uraemic cardiomyopathy and pericarditis. Adv Nephrol Necker Hosp 1980; 9: 33-70.
81. Bechar M, Lakke JP, van der Hem GK, Beeks JW, Penning L. Subdural hematoma during long term hemodialysis. Arch Neurol 1972; 26: 513-516.
82. Berger HW, Rammohan G, Neff MS. Uraemic pleural effusion: a study in 14 patients on chronic dialysis. Ann Int Med 1975; 82: 362-364.
83. Galen MA, Steinberg SM, Lowrie FG. Hemorrhagic pleural effusion in patients undergoing chronic dialysis. Ann Int Med 1975; 82: 359-361.
84. Bhasin HK, Dana CL. Spontaneous retroperitoneal hemorrhage in chronically hemodialyzed patients. Nephron 1978; 22: 322-327.
85. Milutinovich J, Follette WC, Scribner BH. Spontaneous retroperitoneal bleeding in patients on chronic hemodialysis. Ann Int Med 1977; 86: 189-192.
86. Borra S, Kleinfeld M. Subscapular liver hematoma in a patient on chronic hemodialysis. Ann Int Med 1980; 93: 574-575.
87. Slusher MM, Hamilton RW. Letter: spontaneous hyphema during hemodialysis. N Engl J Med 1975; 293: 561.
88. Andrassy K, Ritz E. Uremia as a cause of bleeding. Am J Nephrol 1985; 5: 313-319.
89. Fass RJ, Copelan EA, Brandt JT, Moeschberger ML, Ashton JJ. Platelet-mediated bleeding caused by broad-spectrum penicillins. J Infect Dis 1987; 155: 1242.
90. Shattil S, Bennett J, McDonough M, Turnbull J. Carbenicillin and penicillin G inhibit platelet function in vitro by impairing the interaction of agonists with the platelets surface. J Clin Invest 1980; 65: 329-337.
91. Bang N, Tessler S, Heidenreich R, Marks C. Effects of moxolactan on blood coagulation and platelet function. Rev Infect Dis 1982; 4: S546-S554.
92. Bechtold H, Andrassy K, Jahnchen E, Koderisch J, Koderisch H, Weilemann LS, Sonntag HG, Ritz E. Evidence for impaired hepatic Vitamin K metabolism in patients treated with N-methyl-thiotetrazole cephalosporin. Thromb Haemost 1984; 51: 358-361.
93. Harter HR, Burch JW, Majerus PW, Stanford N, Delmez JA, Anderson CB, Weerts CA. Prevention of thrombosis in patients on hemodialysis by low dose of aspirin. N Engl J Med 1979; 301: 577-579.
94. Lindsay RM, Ferguson D, Prentice CR, Burton JA, McNicol GP. Reduction of thrombus formation on dialyser membranes by aspirin and RA233. Lancet 1972; 2: 1287-1290.
95. Livio M, Benigni A, Viganò G, Mecca G, Remuzzi G. Moderate doses of aspirin and risk of bleeding in renal failure. Lancet 1986; 1: 414-416.
96. Gaspari F, Viganò G, Orisio S, Bonati M, Livio M, Remuzzi G. Aspirin prolongs bleeding time in uremia by a mechanism distinct from platelet cyclooxygenase inhibition. J Clin Invest 1987; 79: 1788-1797.
97. Zuckerman GR, Cornette GL, Clouse RE, Harter HR. Upper gastrointestinal bleeding in patients with chronic renal failure. Ann Intern Med 1985; 102: 588-592.
98. Boyle JM, Johnston B. Acute upper gastrointestinal hemorrhage in patients with chronic renal disease.Am J Med 1983; 75: 409-412.
99. Remuzzi G, Marchesi D, Livio M, Cavenaghi AE, Mecca G, Donati MB, de Gaetano G. Altered platelet and vascular prostaglandin-generation in patients with renal failure and prolonged bleeding times. Thromb Res 1978; 13: 1007-1015.
100. van de Wetering J, Westendorp RGJ, van der Hoeven JG, Stolk B, Feuth JDM, Chang PC. Heparin use in continuous renal replacement procedures: the struggle between filter coagulation and patient hemorrhage. J Am Soc Nephrol 1996; 7: 145-150.
101. Gordon LA, Somon ER, Rukes JM, Richards V, Perkins HA. Studies in regional heparinization. N Engl J Med 1956; 255: 1063-1066.
102. Maher JF, Lapierre L, Schreiner GE, Geiger M, Westervelt JB. Regional heparinization for hemodialysis. N Engl J Med 1963; 268: 451-456.
103. Lindholm DD, Murray JS. A simplified method of regional heparinization during hemodialysis according to a predetermined dosage formula. Trans Am Soc Artif Int Organs 1964; 10: 92-97.
104. Blaufox MD, Hampers CL, Merril JP. Rebound anticoagulation occurring after regional heparinization for hemodialysis. Trans Am Soc Artif Int Organs 1966; 12: 207-209.
105. Lohr YW, Schwab S. Minimizing hemorrhagic complications in dialysis patients. J Am Soc Nephrol 1991; 2: 961-975.
106. Lowr JV, Slussher S, Diederich D. Safety of regional citrate hemodialysis in acute renal failure. Am J Kidney Dis 1989; 2: 104-407.
107. Flanigan MJ, Von Brecht J, Freeman RM, Lim VS. Reducing the hemorragic complications of hemodialysis: a controlled comparison of low-dose heparin and citrate anticoagulation. Am J Kidney Dis 1987; 9: 147-153.
108. Janssen JFM, Deegens JK, Kapinga TH, Beukhof JR, Huijgens PC, van Loenen AC, van der Meulen J. Citrate compared to low molecular weight heparin anticoagulation in chronic hemodialysis patients. Kidney Int 1996; 49: 806-813.
109. Silverstein FJ, Oster JR, Perez GO, Materson BJ, Lopez Ra, Al-Reshaid K. Metabolic alkalosis induced by regional citrate hemodialysis. ASAIO Trans 1989; 35: 22-25.
110. Kelleher SP, Schulman G. Severe metabolic alkalosis complicating regional citrate hemodialysis. Am J Kidney Dis 1987; 9: 235-236.
111. Flanigan MJ, Pillsbury L, Sadewasser G, Lim VS. Regional Hemodialysis Anticoagulation: Hypertonic Trisodium citrate or Anticoagulant Citrate Dextrose A. Am J Kidney Dis 1996; 27.4: 519-524.
112. Tolkoff-Rubin NE, Nardini J, Fang LST, Rubin RH. Successful hemodialysis of patients at high risk of hemorrhage using the ExVal dialyzer. Dial Transplant 1986; 15: 125-126.
113. Liungser B. A low molecular heparin fraction as an anticoagulant during hemodialysis. Clin Nephrol 1985; 25: 15-20.
114. Vanholder RC, Camez AA, Veys NM, Sovia Y, Mirshahi M, Soria C, Ringoir S. Recombinant hirudin: a specific thrombin inhibiting anticoagulant for hemodialysis. Kidney Int 1994; 45: 1745-1749.
115. van Wijk V, Badenhorst PN, Luus HG, Kotze HF. A comparison between use of recombinant hirudin and heparin during hemodialysis. Kidney Int 1995; 48: 1338-1343.
116. Nurmohamed MT, Hoek JA, Ten Cate JW, Krediet RT, Büller HR. A randomized cross-over study comparing the efficacy and safety of two dosages dermatan sulfate and standard heparin in six chronic hemodialysis patients. Br J Haematol 1990; 76(suppl): 23.
117. Ryan KE, Lane DA, Flynn A, Ireland H, Boisclair M, Shepperd J, Curtis JR. Antithrombotic properties of dermatan sulphate (MF 701) in hemodialysis for chronic renal failure. Thromb Haemost 1992; 68: 563-569.
118. Fernandez F, van Ryn J, Ofosu F, Hirsh J, Buchanan MR. The haemorragic and antithrombotic effects of dermatan sulphate. Br J Haematol 1986; 64: 309-317.
119. Lane DA, Ryan K, Ireland H, Ryan K, Ireland H, Curtis JR, Nurmohamed MT, Krediet RT, Roggekamp MC, Stevens P, ten Cate JW. Dermatan sulphate in haemodialysis. Lancet 1992; 339: 334-335.
120. Nurmohamed MT, Knipscheer HC, Stevens P, Krediet RT, Roggekamp MC, Berckmans RJ, ten Cate JW. Clinical experience with a new anticoagulant (dermatan sulphate) in chronic hemodialysis patients. Clin Nephrol 1993; 39: 166-171.
121. Gianese F, Nurmohamed MT, Imbimbo BP, Buller HR, Berckmans RJ, Ten Cate JW. The pharmacodynamics of dermatan sulphate MF 701 during haemodialysis for chronic renal failure. Br J Clin Pharmacol 1993; 35: 335-339.
122. Nurmohamed MT, Knipscheer HC, Gianese F, Büller HR, Stevens P, Roggekamp MC, ten Cate JW. No clinically relevant accumulation of dermatan sulfate (DS) during chronic use in hemodialysis (abstr). Thromb Haemost 1993; 69: 1118.
123. Boccardo P, Melacini D, Rota S, Mecca G, Boletta A, Casiraghi F, Gianese F. Individualized anticoagulation with dermatan sulphate for haemodialysis in chronic renal failure. Nephrol Dialysis Transpl 1997; 12: 2349-2354.
124. Dawson A, Lawinski C, Weston M. Sulfinpyrazone as a method of keeping dialysis membranes clean. In: Frost TH, ed. Technical aspects of Renal Disease. Bath: Pitman Press, 1978.
125. 1 to eliminate platelet and white blood cell losses resulting from hemoperfusion through charcoal albumin, aragose gel and neural and neutral and cation exchange resus. J Lab Clin Nephrol 1985; 24: 15-20.
126. Morring K, Sinn H, Schuler HW. Comparative evaluation of iatrogenic sources of blood loss during maintenance dialysis. In Proceedings of the 13th Congress of European Dialysis and Transplant Association. Tunbridge Wells: Pitman Medical, 1976: 223.
127. Turney JH, Fewell MR, Williams LC, Person V, Weston MJ. Platelet protection and heparin sparing with prostacyclin during regular therapy. Lancet 1980; 2: 219-222.
128. Arze RS, Ward MK. Prostacyclin safer than heparin in haemodialysis. Lancet 1981; 2: 50.
129. Zusman RM, Rubin RH, Cato AE, Cocchetto DM, Crow JW, Tolkoff-Rubin N. Hemodialysis using prostacyclin instead of heparin as the sole antithrombotic agent. N Engl J Med 1981; 304: 934-939.
130. Swartz RD, Flamenbaum W, Dubrow A, Hall JC, Crow JW, Cato A. Epoprostenol (PGI, prostacyclin) during high risk hemodialysis: preventing further bleeding complications. J Clin Pharmacol 1988; 28: 818-825.
131. 2) versus heparin in hemodialysis. Trans Am Soc Artif Int Organs 1984; 30: 52-54.
132. Jacons J, Shoemaker C, Ruderdorf R. Isolation and characterization of genomic and cDNa clones of human erythropoietin-rich plasma in vivo. J Clin Invest 1984; 74: 434-441.
133. Ward DM, Mehta RL. Extracorporeal management of acute renal failure patients at high risk of bleeding. Kidney Int 1993; 41: S237-S244.
134. Sanders PW, Taylor H, Curtis JJ. Hemodialysis without anticoagulation. Am J Kidney Dis 1985; 5: 32-35.
135. Lin FK, Suggs S, Lin CH. Cloning and expression of the human erythropoietin gene. PNAS USA 1985; 82: 7580-7584.
136. Winearls CG, Oliver DO, Pippard MJ, Reid C, Downing MR, Coter PM. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic hemodialysis. Lancet 1986; 2: 1175-1178.
137. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia and end-stage renal disease with recombinant human erythropoietin: results of a phase I and II clinical trial. N Engl J Med 1987; 316: 73-78.
138. Zwaginga JJ, Ijsseldijk MJW, de Groot PG, Kooistra M, Vos J, van-Es A, Koomans HA, Struyvenberg A, Sixma JJ. Treatment of uraemic anemia with recombinant erythropoietin also reduces the defects in platelet adhesion and aggregation caused by uraemic plasma. Thromb Haemost 1991; 66: 638-647.
139. Suraib S, Al-Momen AK, Gader AMA. Effect of recombinant human erythropoietin in chronic hemodialysis patients. Thromb Haemost 1989; 61: 117.
140. Triulzi DJ, Blumberg N. Variability in response to cryoprecipitate treatment for hemostatic defects in uremia. Yale J Biol Med 1990; 63: 1-7.
141. Mannucci PM, Ruggeri ZM, Pareti FI, Capitanio A. 1-Deamino-8D-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrand’s disease. Lancet 1977; 1: 869-872.
142. Canavese C, Salomone M, Mangiarotti G, Calitri V. Reduced response of uraemic bleeding time to repeated doses of desmopressin. Lancet 1985; 1: 867-868.
143. Shapiro MD, Kelleher SP. Intranasal deamino-8-D-arginine vasopressin shortens the bleeding time in uremia. Am J Nephrol 1984; 4: 260-261.
144. Rydzewski A, Rowinski M, Mysliwiec M. Shortening of the bleeding time after intranasal administration of 1-deamino-8-D-arginine vasopressin to patients with chronic anemia. Folia Haematol Int Mag Klin Morphol Blut Forsch 1986; 113: 823-830.
145. Viganò G, Mannucci PM, Lattuada A, Harris A, Remuzzi G. Subcutaneous desmopressin (DDAVP) shortens the bleeding time in uremia. Am J Hematol 1989; 31: 32-35.
146. Byrnes JJ, Larcada A, Moake JL. Thrombosis following desmopressin for uremic bleeding. Am J Hematol 1988; 28: 63-65.
147. Liu YK, Kosfeld RE, Marcum SG. Treatment of uraemic bleeding with conjugated oestrogen. Lancet 1984; 2: 887-890.
148. Livio M, Mannucci PM, Vigano GL, Mingardi G, Lombardi R, Mecca G, Remuzzi G. Conjugated estrogens for the management of bleeding associated with renal failure. N Engl J Med 1986; 315: 731-735.
149. Viganò G, Gaspari F, Locatelli M, Pusineri F, Bonati M, Remuzzi G. Dose-effect and pharmacokinetics of estrogens given to correct bleeding time in uremia. Kidney Int 1988; 34: 853-858.
150. Sloand JA, Schiff MJ. Beneficial effect of low-dose transdermal estrogen on bleeding time and clinical bleeding in uremia. Am J Kidney Dis 1995; 26: 22-25.
151. Zoja C, Noris M, Corna D, Viganò G, Perico N, de Gaetano G, Remuzzi G. L-Arginine, the precursor of nitric oxide, abolishes the effect of estrogens on bleeding time in experimental uremia. Lab Invest 1991; 65: 479-483.